Business
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
- Dr. Stanley Appel to present data from a proof-of-concept open-label clinical study in patients with ALS. - ALS patients were treated with Coya’s
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":"\n - Dr. Stanley Appel to present data from a proof-of-concept open-label clinical study in patients with ALS.\n\n - ALS patients were treated with Coya’s investigational biologic combination (COYA 302) administered subcutaneously over a 12-month period.\n\n - The study evaluated safety and tolerability, regulatory T cell (Treg) function, serum blood biomarkers, and clinical status and function (ALSFRS-R scale).\n\n HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing multiple therapeutic platforms intended to enhance Treg function, including biologics and cell therapies, today announced the presentation of results from an academic clinical study in patients with Amyotrophic Lateral Sclerosis (ALS) with Coya’s proprietary investigational biologic combination at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, to be held in-person and virtually from March 19 to March 22, 2023.\n\nThe proof-of-concept open-label clinical study is the first-of-its-kind evaluating a dual-mechanism immunotherapy for the treatment of ALS. Patients in the study received investigational treatment for 12 consecutive months and were evaluated for safety and tolerability, Treg function, serum biomarkers of oxidative stress and inflammation, and clinical functioning as measured by the ALSFRS-R scale. The dual-mechanism investigational biologic combination combines low dose Interleukin-2 that is intended to enhance anti-inflammatory regulatory T cell function with a fusion protein that is intended to suppress pro-inflammatory cell function and has been designed to be administered subcutaneously to minimize treatment burden for patients and caregivers.\n\nALS is a disease of the parts of the nervous system that control voluntary muscle movement. In ALS, motor neurons (nerve cells that control muscle cells) are gradually lost. As these motor neurons are lost, the muscles they control become weak and then nonfunctional, thus leading to muscle weakness, disability, and eventually death. ALS is the most common form of motor neuron disease.\n\nThe study was conducted at the Houston Methodist Research Institute (Houston, Texas) by Stanley Appel, M.D., Jason Thonhoff, M.D., Ph.D., and David Beers, Ph.D.\n\nDr. Appel is chair of Coya’s Scientific Advisory Board a...